Trials Sponsors Conditions Drugs Pricing

Conditions

Cholestatic Liver Disease Hepatobiliary Cancer Intrahepatic Cholestasis Progressive Familial Intrahepatic Cholestasis

Outcome Measures

Primary Outcomes (1)

Mutation classification in PFIC genes in patients with CCLDs
Estimate the percentage of pathological mutations, probably pathological, variants to uncertain significance, probably benign, benign in PFIC genes in subjects with CCLDs
12 months

Secondary Outcomes (2)

Clinical Outcomes in PFIC Gene Mutation Carriers
12 months
Histological Patterns of Familial Intrahepatic Cholestasis in PFIC Gene Mutation Carriers
12 months

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Data from all patients with PFIC/CCLDs/HBCs will be collected and retrospectively evaluated relating to the centers participating in the study from May 2013 until the start date of the study.

You may qualify if:

age ≥ 18 years

Sponsors & Collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Otherlead

Study Sites (2)

IRCCS - Azienda Ospedaliero-Universitaria di Bologna

Bologna, Bologna, 40138, Italy

RECRUITING

Giovanni Vitale, PhD, MDCONTACT0512144187 giovanni.vitale@aosp.bo.it

Ospedale Civile Sant'Agostino Estense Baggiovara

Modena, Modena, 41126, Italy

RECRUITING

Pietro AndreoneCONTACT0594223481

MeSH Terms

Conditions

Cholestasis, IntrahepaticCholestasis, progressive familial intrahepatic 1

Condition Hierarchy (Ancestors)

CholestasisBile Duct DiseasesBiliary Tract DiseasesDigestive System DiseasesLiver Diseases

Study Officials

Giovanni Vitale, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
PRINCIPAL INVESTIGATOR

Central Study Contacts

Giovanni Vitale, MD

CONTACT

0512144187 giovanni.vitale@aosp.bo.it

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 3, 2024

First Posted

January 17, 2025

Study Start

January 16, 2024

Actual (reported)

Primary Completion

January 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

Primary Completion

First Posted

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

Primary Completion

First Posted

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations